脓毒症患者发生心肌损伤的高危因素分析

doi:10.20223/j.cnki.1000-8535.2025.10.003

摘要/Abstract

摘要： 脓毒症当前仍然是全球范围内重要的医疗卫生问题,其对世界公共卫生及患者安全带来重大威胁。脓毒症是指宿主对感染反应失调引起的危及生命的器官功能障碍,其发病率和病死率均极高,是临床重症医学中的重大挑战。在脓毒症病情的进展过程中,可出现组织灌注不足、血流动力学不稳定等变化,从而导致多器官功能受损,而心脏是常见的被累及的重要靶器官之一,这种由脓毒症所导致的不同程度的心肌损伤,被称为“脓毒性心肌病”,其发生和发展机制复杂多样,涉及循环心肌抑制因素、心肌自身因素及自主神经失调等多个方面。文章综述了脓毒症患者发生心肌损伤的高危因素,以期为临床治疗和预防提供参考。

关键词: 脓毒症, 脓毒性休克, 心肌损伤, 高危因素

Abstract: Sepsis currently remains an important global healthcare issue,and a major threat to world public health and patient safety．Sepsis is a life-threatening organ dysfunction caused by dysregulation of the host response to infection,with extremely high morbidity and mortality,which is a major challenge in clinical critical care medicine．During the progression of sepsis,changes such as inadequate tissue perfusion and haemodynamic instability may occur,leading to impairment of multiple organ functions,while the heart is one of the commonly involved vital target organs,and the varying degree of myocardial damage caused by sepsis is known as “septic cardiomyopathy”．The mechanisms of its occurrence and development are complex and diverse,involving circulating myocardial inhibitory factors,myocardial auto-factors,and autonomic dysregulation．In this paper,we review the high-risk factors for myocardial injury in septic patients,providing a reference for clinical treatment and prevention.

Key words: sepsis, septic shock, septic cardiomyopathy, risk factors

董基毅, 陆金帅. 脓毒症患者发生心肌损伤的高危因素分析[J]. 广州医药, 2025, 56(10): 1338-1345.

DONG Jiyi, LU Jinshuai. High-risk factors for the development of myocardial injury in patients with sepsis[J]. Guangzhou Medical Journal, 2025, 56(10): 1338-1345.

参考文献

[1] 高瑞,秦祺舒,曹丽萍,等.关于脓毒症认识的历史回顾[J].中国急救医学,2024,44(8):698-702.
[2] 朱玉菡,陈腾飞,宋麦芬,等.心肌损伤对ICU脓毒症患者的影响及其危险因素分析的临床研究[J].中国循证心血管医学杂志,2023,15(3):336-340.
[3] 李心瑶,陈俊,李灼.脓毒症心肌病的发病机制研究进展[J].心血管病学进展,2024,45(1):44-47,61.
[4] MUNIZ-SANTOS R,LUCIERI-COSTA G,de ALMEIDA M,et al.Lipid oxidation dysregulation:An emerging player in the pathophysiology of sepsis[J].Front Immunol,2023(14):1224335.
[5] MARTIN L,DERWALL M,AL ZOUBI S,et al.The septic heart:Current understanding of molecular mechanisms and clinical implications[J].Chest,2019,155(2):427-437.
[6] FAVERO A M,ROSALES T O,SCHESCHOWITSCH K,et al.Blockade of sympathetic ganglia improves vascular dysfunction in septic shock[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(9):6551-6562.
[7] LU J,LIU J,ZHU L,et al.The effect of age on the clinical characteristics and innate immune cell function in the patients with abdominal sepsis[J].Front Physiol,2022(13):952434.
[8] 吴刘丽,赵景霖,贾雄飞,等.脓毒症心肌损伤的新型治疗药物研究进展[J].山东医药,2023,63(35):104-108.
[9] 周子阳,唐建国,徐丹,等.不同病原学结果血流感染脓毒症患者PT、NLR、PCT/ALB的变化及其与预后的关系研究[J].现代生物医学进展,2024,24(5):858-862.
[10] 李景萍. 革兰氏阴性细菌感染致脓毒症患者血清免疫、炎性指标与心肌损伤的相关性[J].临床医学,2023,43(11):55-57.
[11] 黄颖,唐立丽,关于琳,等.脓毒症心肌损伤发病机制及治疗研究进展[J].实用医学杂志,2023,39(14):1848-1852.
[12] ENDLICHER R,DRAHOTA Z,STEFKOVA K,et al.The mitochondrial permeability transition pore-current knowledge of its structure,function,and regulation,and optimized methods for evaluating its functional state[J].Cells,2023,12(9):1273.
[13] SEN P,GUPTA K,KUMARI A,et al.Wnt/β-catenin antagonist pyrvinium exerts cardioprotective effects in polymicrobial sepsis model by attenuating calcium dyshomeostasis and mitochondrial dysfunction[J].Cardiovasc Toxicol,2021,21(7):517-532.
[14] ZHOU Q,XIE M,ZHU J,et al.PINK1 contained in huMSC-derived exosomes prevents cardiomyocyte mitochondrial calcium overload in sepsis via recovery of mitochondrial Ca2+ efflux[J].Stem Cell Res Ther,2021,12(1):269.
[15] CARRARA M,FERRARIO M,BOLLEN P B,et al.The autonomic nervous system in septic shock and its role as a future therapeutic target:A narrative review[J].Ann Intensive Care,2021,11(1):80.
[16] 童飞,房晓伟,朱春艳,等.低镁血症对重症脓毒症患者预后的影响[J].中华危重病急救医学,2022,34(1):23-27.
[17] ZHAI Y,YAO Q,THE E,et al.Aging exacerbates cardiac dysfunction and mortality in sepsis through enhancing TLR2 activity[J].Front Cardiovasc Med,2023(10):1293866.
[18] 符会妮,吕树志,余君.心力衰竭病史、冠心病病史及乳酸值对脓毒性心肌病的诊断价值分析[J].齐齐哈尔医学院学报,2020,41(18):2262-2264.
[19] 王勇涛. 脓毒症心肌病发病机制的探讨[J].中国急救医学,2016,36(2):120-125.
[20] GITONGA E N,WANG J,YU S,et al.Left ventricular dysfunction and reversible pulmonary hypertension secondary to severe pneumonia in a background of sepsis:A case report and review of the literature[J].Ann Palliat Med,2020,9(5):3629-3642.
[21] HE W,ZHANG W,AN Y,et al.Impact of pulmonary arterial hypertension on systemic inflammation,cardiac injury and hemodynamics in sepsis:A retrospective study From MIMIC-III[J].Am J Med Sci,2022,363(4):311-321.
[22] TARTAVOULLE T M.Management of sepsis in patients with pulmonary arterial hypertension in the intensive care unit[J].Crit Care Nurs Clin North Am,2017,29(1):15-23.
[23] VASUDEVA R,CHALLA A,TUCK N,et al.Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock[J].BMC Pulm Med,2022,22(1):374.
[24] OH G C,CHO H J.Blood pressure and heart failure[J].Clin Hypertens,2020(26):1.
[25] LASICA R,DJUKANOVIC L,VUKMIROVIC J,et al.Clinical review of hypertensive acute heart failure[J].Medicina(Kaunas),2024,60(1):133.
[26] LI X M,JIANG L,GUO Y K,et al.The additive effects of type 2 diabetes mellitus on left ventricular deformation and myocardial perfusion in essential hypertension:A 3.0 T cardiac magnetic resonance study[J].Cardiovasc Diabetol,2020,19(1):161.
[27] ASGHARI A A,MAHMOUDABADY M,MOUSAVI E Z,et al.Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes[J].J Food Biochem,2022,46(12):e14494.
[28] 黄平,杜治祥,梁结玲,等.脓毒症心血管功能损伤与脏器功能评估中脓毒症相关标记物的应用价值探讨[J].齐齐哈尔医学院学报,2020,41(14):1730-1732.
[29] ANGRIMAN F,LAWLER P R,SHAH B R,et al.Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors:A population-based cohort study[J].Crit Care,2023,27(1):302.
[30] 董俊峰,夏胜兵.糖尿病合并脓毒症患者住院期间不良心血管事件发生情况分析[J].中国卫生工程学,2023,22(2):198-200.
[31] SCALZO N,CANASTAR M,LEBOVICS E.Part 1:Disease of the heart and liver:A relationship that cuts both ways[J].Cardiol Rev,2022,30(3):111-122.
[32] KAUR H,PREMKUMAR M.Diagnosis and management of cirrhotic cardiomyopathy[J].J Clin Exp Hepatol,2022,12(1):186-199.
[33] 熊峰,杨宏锋,颜骏,等.重症监护病房脓毒症患者发生高动力左室射血分数的原因及预后分析[J].中华危重病急救医学,2023,35(8):834-838.
[34] 赵国敏,边伟帅,甄洁,等.血清钾、钙、镁对评估脓毒症患者预后的临床价值[J].中国老年学杂志,2024,44(5):1075-1079.
[35] 李磊. 血清镁水平对急诊危重患者病情进展及预后的影响[J].系统医学,2020,5(18):47-49.
[36] LIMAYE C S,LONDHEY V A,NADKART M Y,et al.Hypomagnesemia in critically ill medical patients[J].J Assoc Physicians India,2011(59):19-22.
[37] 夏吉英. 联用黄芪注射液、复方丹参注射液和加镁极化液治疗冠状动脉粥样硬化性心脏病90例疗效观察[J].中国中西医结合急救杂志,1999,6(2):88.
[38] 张艳,宋芹,王元新,等.脓毒症合并低钙血症患者预后的影响因素[J].保健医学研究与实践,2023,20(7):31-35.
[39] 桑珍珍,郭晋平,贾春梅,等.脓毒性心肌病的危险因素分析及早期治疗[J].临床急诊杂志,2017,18(6):416-419.
[40] IBA T,UMEMURA Y,WADA H,et al.Roles of coagulation abnormalities and microthrombosis in sepsis:Pathophysiology,diagnosis,and treatment[J].Arch Med Res,2021,52(8):788-797.
[41] MARTIN L,KOCZERA P,ZECHENDORF E,et al.The endothelial glycocalyx:New diagnostic and therapeutic approaches in sepsis[J].Biomed Res Int,2016(2016):3758278.
[42] MCGEE M P,CHOU T.Surface-dependent coagulation enzymes.Flow kinetics of factor Xa generation on live cell membranes[J].J Biol Chem,2001,276(11):7827-7835.
[43] DENG Z,HE M,HU H,et al.Melatonin attenuates sepsis-induced acute kidney injury by promoting mitophagy through SIRT3-mediated TFAM deacetylation[J].Autophagy,2024,20(1):151-165.
[44] 廖夕茗,杨国辉.凝血功能紊乱在脓毒症心肌损伤发病机制中作用研究进展[J].疑难病杂志,2024,23(8):1002-1005,1010.
[45] 王妍,张北源,郭晓芳,等.重症患者局部枸橼酸抗凝行连续性静脉-静脉血液滤过离子钙浓度的探讨[J].肾脏病与透析肾移植杂志,2021,30(2):119-123.
[46] MARIK P E,BYRNE L,van HAREN F.Fluid resuscitation in sepsis:The great 30 mL per kg hoax[J].J Thorac Dis,2020,12(Suppl 1):S37-S47.
[47] 张新超,温伟,董士民.老年脓毒症诊断与治疗中的困难与挑战[J].中国急救医学,2024,44(5):376-384.
[48] EVANS L,RHODES A,ALHAZZANI W,et al.Surviving sepsis campaign:International guidelines for management of sepsis and septic shock 2021[J].Crit Care Med,2021,49(11):e1063-e1143.
[49] SEMLER M W,SELF W H,WANDERER J P,et al.Balanced crystalloids versus saline in critically ill adults[J].N Engl J Med,2018,378(9):829-839.
[50] ALTHAGAFI T H,QARTALI A A,ALASMARI N H,et al.Adverse effects of fluid overload in different paediatric age groups[J].Int J Community Med Public Health,2022,9(10):3960.
[51] ALTHAGAFI T H,QARTALI A A,ALASMARI N H,et al.Adverse effects of fluid overload in different paediatric age groups[J].Int J Community Med Public Health,2022,9(10):3960.
[52] ZHOU Y,WANG Y,LI Q,et al.The effects of early restrictive fluid resuscitation on the clinical outcomes in sepsis patients[J].Am J Transl Res,2021,13(10):11482-11490.